PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 26, 2026The Journal of Clinical Endocrinology & Metabolism2 citationsOpen Access

Cardiac Safety of Chronic Inhibition of the Myostatin-Activin Pathway with Bimagrumab in Healthy Older Adults

View Full Paper
DRDaniel RooksDYDenise P. YatesSNSrikanth Neelakantham

Key Points

  • The aim is to evaluate the impact of bimagrumab on cardiac structure and function in older adults while inhibiting the myostatin-activin pathway.
  • Conducted over six months
  • Compared bimagrumab with a placebo
  • Focus on healthy older adults
  • Bimagrumab showed no significant effects on cardiac structure
  • No impact on cardiac function compared to placebo
  • Supports its use for muscle sparing during weight loss

Abstract

Six months of myostatin-activin pathway inhibition with bimagrumab had no effect on cardiac structure or function in healthy older adults compared to placebo. These results support consideration of bimagrumab as a skeletal muscle sparing intervention in adults undergoing weight loss with GLP-1 receptor agonists.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Rooks et al. (2026) studied this question.

synapsesocial.com/papers/69c4cd05fdc3bde448918c7bhttps://doi.org/10.1210/clinem/dgag091
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bimagrumab: Novel Medical Therapy for Inclusion Body Myositis, Sarcopenia, and Medication-Induced Lean Body Mass Loss2025
  2. 2Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials2026
  3. 3An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy2013 · 303 citations
  4. 4Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial2026 · 49 citations
  5. 5Preclinical development of an extended half-life anti-myostatin monoclonal antibody2026